Evaluation of the therapeutic potential of pericytes and mesenchymal stromal cells in SOD1 mice, animal model for amyotrophic lateral sclerosis

Author(s)

Giuliana Castello Coatti

• Document type: Doctoral Thesis
• Press: São Paulo.
• Institution: Universidade de São Paulo (USP). Instituto de Biociências (IBIOC/SB)
• Defense date: 2015-08-14

Examining board members

Mayana Zatz; Merari de Fatima Ramires Ferrari; Oswaldo Keith Okamoto; Jean Pierre Schatzmann Peron; Alexander Henning Ulrich

• Advisor: Mayana Zatz

Abstract

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig\'s disease, is the most common form of motor neuron disease. Most cases are characterized by an adult onset of symptoms, usually in the fourth or fifth decade of life, affecting both upper and lower motor neurons. The degeneration caused by ALS is progressive and irreversible. On average, the survival ranges from 3 to 5 years after onset, mainly due to respiratory failure. Currently, the only Food and Drug Administration (FDA)-approved medication for this disorder is Riluzole, but its effects on survival are minimal. In this scenario, cell therapy is being evaluated as a possible alternative. Preclinical studies indicate beneficial effects of treatment of SOD1 mice (animal model for ALS) with mesenchymal stromal cells or simply mesenchymal cells (MSCs), mainly attributed to the action of soluble factors. Here we propose the use of pericytes, a cell line not yet tested for preclinical treatment in of ALS. Pericytes are perivascular cells surrounding endothelial cells and play important cellular roles such as assistance of formation and maintenance of the blood-brain barrier, which is essential to protect the central nervous system from damage in neurodegenerative diseases. Thus, this study sought to compare the therapeutic potential of mesenchymal cells and pericytes, both obtained from the same human adipose tissue, in SOD1 mice. For this purpose, survival and physical performance (weight, PaGE, motor score and rotarod) were evaluated. Except for the benefits observed in PaGE and the motor score tests in an early stage of the disease, treatment with MSCs and pericytes does not result in significant effects on disease progression of SOD1 female mice. For males, treatment with pericytes stands out compared to treatment with MSCs or HBSS (vehicle), resulting in beneficial effects on survival and in certain physical functions of the animals, particularly for the motor score and rotarod tests, where improvement was observed in the initial stage of the disease. The analysis of gene expression in the brain and spinal cord in end-stage animals suggests that treatment of males with pericytes can stimulate the animals\' antioxidant defense. No traces of injected human cells were observed in brain or spinal cord of mice, indicating a possible systemic effect of the transplant (AU)

• FAPESP's process: 13/03166-7 - Therapeutic Efect of mesenchymal stromal cells (MSC) and pericytes in a model for amyotrophic lateral sclerosis (ALS)
• Grantee: Giuliana Castello Coatti
• Support Opportunities: Scholarships in Brazil - Doctorate